
Cytomegalovirus (HHV-5) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Cytomegalovirus (HHV-5) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cytomegalovirus (HHV-5) Infections - Drugs In Development, 2022, provides an overview of the Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline landscape.
Cytomegalovirus (CMV) is a contagious infection of the caused by the member of the herpes virus family. CMV is spread through saliva or urine. Symptoms include fever, pneumonia, weight loss, hearing, neurological and developmental problems. The predisposing factors are exposure direct contact with infected surface or organism, weakened immune system and congenital factors. It may be diagnosed by blood or urine tests. The condition may be controlled by the use of medication such as anti-viral and may be prevented by lifestyle modification.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cytomegalovirus (HHV-5) Infections - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Cytomegalovirus (HHV-5) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Cytomegalovirus (HHV-5) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 5, 6, 9, 23, 9 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 2, 11, 11, 2, 8 and 4 molecules, respectively.
Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cytomegalovirus (HHV-5) Infections - Drugs In Development, 2022, provides an overview of the Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline landscape.
Cytomegalovirus (CMV) is a contagious infection of the caused by the member of the herpes virus family. CMV is spread through saliva or urine. Symptoms include fever, pneumonia, weight loss, hearing, neurological and developmental problems. The predisposing factors are exposure direct contact with infected surface or organism, weakened immune system and congenital factors. It may be diagnosed by blood or urine tests. The condition may be controlled by the use of medication such as anti-viral and may be prevented by lifestyle modification.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cytomegalovirus (HHV-5) Infections - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Cytomegalovirus (HHV-5) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Cytomegalovirus (HHV-5) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 5, 6, 9, 23, 9 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 2, 11, 11, 2, 8 and 4 molecules, respectively.
Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Cytomegalovirus (HHV-5) Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Cytomegalovirus (HHV-5) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Cytomegalovirus (HHV-5) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Cytomegalovirus (HHV-5) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Cytomegalovirus (HHV-5) Infections (Infectious Disease)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Cytomegalovirus (HHV-5) Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
154 Pages
- Introduction
- Global Markets Direct Report Coverage
- Cytomegalovirus (HHV-5) Infections – Overview
- Cytomegalovirus (HHV-5) Infections – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Cytomegalovirus (HHV-5) Infections – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Cytomegalovirus (HHV-5) Infections – Companies Involved in Therapeutics Development
- Abhelix LLC
- Acer Therapeutics Inc
- AlloVir Inc
- AlphaVax Inc
- Artemis Therapeutics Inc
- Biotest AG
- Chengdu Rongsheng Pharmaceutical Co Ltd
- China Biologic Products Holdings Inc
- China Immunotech Co Ltd
- Citranvi Biosciences LLC
- Cyrus Biotechnology Inc
- Danuvius BioSciences
- Evrys Bio
- GSK plc
- Helocyte Biosciences Inc
- Hookipa Pharma Inc
- Huinuo Biomedical Technology Co Ltd
- iCELL Biotechnology Co Ltd
- Immunetune BV
- Karyopharm Therapeutics Inc
- Lion TCR Pte Ltd
- Memo Therapeutics AG
- Merck & Co Inc
- Microbiotix Inc
- Moderna Inc
- Nobelpharma Co Ltd
- Okogen Inc
- Phoenix Biotechnology Inc
- Prosit Sole Biotechnology (Beijing) Co Ltd
- Savoy Pharmaceuticals Inc
- Shanxi Kangbao Biological Product Co Ltd
- SL VaxiGen Inc
- SpyBiotech Ltd
- Stadius Biopharma LLC
- Synklino ApS
- Takeda Pharmaceutical Co Ltd
- Trellis Bioscience Inc
- VBI Vaccines Inc
- Vichem Chemie Research Ltd
- Viramatix Sdn Bhd
- ViroKyne Therapeutics LLC
- Zhuhai Trinomab Biotechnology Co Ltd
- Cytomegalovirus (HHV-5) Infections – Drug Profiles
- Antibody for Cytomegalovirus (HHV-5) Infections – Drug Profile
- Antibody for Human Cytomegalovirus Infection – Drug Profile
- artemisone – Drug Profile
- AVX-601 – Drug Profile
- Bi-specific Monoclonal Antibody to Target CD3 and Glycoprotein B for Cytomegalovirus (HHV-5) Infections – Drug Profile
- BT-084 – Drug Profile
- Cellular Immunotherapy for Cytomegalovirus (HHV-5) Infections – Drug Profile
- Cellular Immunotherapy for Cytomegalovirus (HHV-5) Infections – Drug Profile
- Cellular Immunotherapy for Cytomegalovirus Infection – Drug Profile
- Cellular Immunotherapy for Cytomegalovirus Infections – Drug Profile
- Cellular Immunotherapy for Cytomegalovirus Infections – Drug Profile
- Cellular Immunotherapy for Cytomegalovirus Infections – Drug Profile
- Cellular Immunotherapy for Cytomegalovirus Infections – Drug Profile
- Cellular Immunotherapy for Cytomegalovirus Infections – Drug Profile
- Cellular Immunotherapy for Cytomegalovirus Infections – Drug Profile
- Cellular Immunotherapy for Herpesviridae Infections – Drug Profile
- Cellular Immunotherapy for Infectious Disease – Drug Profile
- Cellular Immunotherapy for Infectious Diseases – Drug Profile
- Cellular Immunotherapy for Infectious Diseases – Drug Profile
- Cellular Immunotherapy for Infectious Diseases – Drug Profile
- Cellular Immunotherapy for Unspecified Cancer and Viral Infections – Drug Profile
- Cellular Immunotherapy for Viral Infections – Drug Profile
- Cellular Immunotherapy for Viral Infections – Drug Profile
- Cellular Immunotherapy for Viral infections – Drug Profile
- Cellular Immunotherapy for Viral Infections – Drug Profile
- Cellular Immunotherapy for Viral Infections – Drug Profile
- Cellular Immunotherapy for Viral Infections – Drug Profile
- Cellular Immunotherapy to Target CMV Antigen for Cytomegalovirus Infections – Drug Profile
- Cellular Immunotherapy to Target PP65 for Cytomegalovirus Infections – Drug Profile
- CG-102 – Drug Profile
- CMV – Drug Profile
- CMV-CTL – Drug Profile
- CMVpp65 – Drug Profile
- Convax – Drug Profile
- Cytomegalovirus [strain AD169] (whole virion) vaccine – Drug Profile
- cytomegalovirus immune globulin (human) – Drug Profile
- Cytomegalovirus vaccine – Drug Profile
- Cytomegalovirus vaccine – Drug Profile
- cytomegalovirus vaccine – Drug Profile
- Cytomegalovirus vaccine – Drug Profile
- cytomegalovirus vaccine 1 – Drug Profile
- Drugs for CMV Retinitis – Drug Profile
- emetine hydrochloride – Drug Profile
- EV-100 – Drug Profile
- filociclovir – Drug Profile
- Gene Therapy for Cytomegalovirus (HHV-5) Infections – Drug Profile
- Gene Therapy for Viral Infections – Drug Profile
- Gene Therapy for Viral Infections Post-HSCT – Drug Profile
- Gene-Modified Cell Therapy for Viral Infections – Drug Profile
- GSK-3993129A – Drug Profile
- HB-101 – Drug Profile
- hCMV Receptor Decoy – Drug Profile
- HN-0141 – Drug Profile
- IMT-100 – Drug Profile
- letermovir – Drug Profile
- LTV-20 – Drug Profile
- maribavir – Drug Profile
- Monoclonal Antibodies to Inhibit Envelope Glycoprotein H for Cytomegalovirus Infections – Drug Profile
- Monoclonal Antibodies to Inhibit gH and gB for Cytomegalovirus Infections – Drug Profile
- Monoclonal Antibody for Cytomegalovirus (HHV-5) Infections – Drug Profile
- Monoclonal Antibody to Agonize LTBR for Cytomegalovirus (HHV-5) Infections – Drug Profile
- mRNA-1443 – Drug Profile
- mRNA-1647 – Drug Profile
- NPC-21 – Drug Profile
- PBI-05204 – Drug Profile
- Pentavalent-Specific T Cells (penta-STs) – Drug Profile
- Peptides to Inhibit Heparan Sulfate for HHV-5 Infections – Drug Profile
- posoleucel – Drug Profile
- PSP-001 – Drug Profile
- SLV-10 – Drug Profile
- Small Molecule to Inhibit DNA Polymerase for Cytomegalovirus (HHV-5) Infections – Drug Profile
- Small Molecules for CMV Infections – Drug Profile
- Small Molecules for CMV infections and Oncology – Drug Profile
- Small Molecules for Cytomegalovirus (HHV-5) Infections – Drug Profile
- Small Molecules for Hepatitis B and Cytomegalovirus (HHV-5) Infections – Drug Profile
- Small Molecules to Activate Sirtuin for Viral Infections – Drug Profile
- SPYVLP-102 – Drug Profile
- Stem Cell Therapy for Cytomegalovirus (HHV-5) Infections – Drug Profile
- SYN-002 – Drug Profile
- Synthetic Peptide to Antagonize VIPR for Cytomegalovirus Infection and Graft Versus Host Disease – Drug Profile
- TF-27 – Drug Profile
- TH-8321 – Drug Profile
- TNM-006 – Drug Profile
- Triplex – Drug Profile
- TRL-345 – Drug Profile
- V-160 – Drug Profile
- valnoctamide – Drug Profile
- VBI-1501 – Drug Profile
- verdinexor – Drug Profile
- Viroprev – Drug Profile
- ViroTCell – Drug Profile
- VMTX-002 – Drug Profile
- Cytomegalovirus (HHV-5) Infections – Dormant Projects
- Cytomegalovirus (HHV-5) Infections – Discontinued Products
- Cytomegalovirus (HHV-5) Infections – Product Development Milestones
- Featured News & Press Releases
- Sep 20, 2022: Health Canada approves Takeda's LIVTENCITY (maribavir) the first and only treatment for adults with post-transplant cytomegalovirus (CMV) infection
- Sep 16, 2022: Takeda receives positive CHMP opinion for maribavir for the treatment of adults with post-transplant cytomegalovirus (CMV) refractory (with or without resistance) to prior therapies
- Aug 11, 2022: Fortress Biotech subsidiary Helocyte announces grant that could provide over $20 million from National Institute of Allergy and infectious diseases for phase 2 study of triplex for control of cytomegalovirus in patients undergoing liver transplantation
- Apr 27, 2022: Clinical trial of potential vaccine for cytomegalovirus
- Apr 22, 2022: Takeda presents new exploratory analysis showing patients treated With LIVTENCITY (Maribavir) had reductions in hospitalization rates and length of hospital stay
- Apr 20, 2022: FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir’s Posoleucel for Prevention of Multiple Life-Threatening Infections from Six Viruses in Allogeneic Hematopoietic Cell Transplant Patients
- Mar 22, 2022: AlloVir initiates global phase 3 registrational study of posoleucel for prevention of life-threatening viral infections from six common viruses in high-risk, allogeneic hematopoietic cell transplant patients
- Mar 22, 2022: Systematic review and meta-analysis of real-world observational studies provide additional evidence of effectiveness of PREVYMIS in preventing cytomegalovirus infection and disease in adults undergoing allogeneic HCT
- Dec 17, 2021: Fortress and Helocyte begin Phase II trial of cytomegalovirus vaccine
- Dec 09, 2021: Takeda’s Phase III CMV infection trial of Livtencity meets primary goal
- Dec 03, 2021: Amber Specialty Pharmacy selected by Takeda to dispense LIVTENCITY (maribavir) for the treatment of adults and pediatric patients with post-transplant CMV infection/disease that is refractory to treatment
- Dec 03, 2021: Newly approved LIVTENCITY (maribavir) now available at Biologics by McKesson
- Dec 02, 2021: Takeda’s LIVTENCITY (maribavir) now available for certain individuals ages 12 years and older with post-transplant cytomegalovirus (CMV) infection/disease in the United States
- Nov 24, 2021: FDA approves Takeda’s Livtencity for post-transplant cytomegalovirus
- Nov 10, 2021: Huaxia Yingtai will announce the latest clinical data of CMV TCR-T at the 63rd Annual Meeting of the American Society of Hematology (ASH)
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Table 1: Number of Products under Development for Cytomegalovirus (HHV-5) Infections, 2022
- Table 2: Number of Products under Development by Companies, 2022
- Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
- Table 4: Number of Products under Development by Companies, 2022 (Contd..2)
- Table 5: Number of Products under Development by Universities/Institutes, 2022
- Table 6: Number of Products under Development by Universities/Institutes, 2022 (Contd..1)
- Table 7: Products under Development by Companies, 2022
- Table 8: Products under Development by Companies, 2022 (Contd..1)
- Table 9: Products under Development by Companies, 2022 (Contd..2)
- Table 10: Products under Development by Companies, 2022 (Contd..3)
- Table 11: Products under Development by Universities/Institutes, 2022
- Table 12: Products under Development by Universities/Institutes, 2022 (Contd..1)
- Table 13: Number of Products by Stage and Target, 2022
- Table 14: Number of Products by Stage and Target, 2022 (Contd..1)
- Table 15: Number of Products by Stage and Mechanism of Action, 2022
- Table 16: Number of Products by Stage and Route of Administration, 2022
- Table 17: Number of Products by Stage and Molecule Type, 2022
- Table 18: Cytomegalovirus (HHV-5) Infections – Pipeline by Abhelix LLC, 2022
- Table 19: Cytomegalovirus (HHV-5) Infections – Pipeline by Acer Therapeutics Inc, 2022
- Table 20: Cytomegalovirus (HHV-5) Infections – Pipeline by AlloVir Inc, 2022
- Table 21: Cytomegalovirus (HHV-5) Infections – Pipeline by AlphaVax Inc, 2022
- Table 22: Cytomegalovirus (HHV-5) Infections – Pipeline by Artemis Therapeutics Inc, 2022
- Table 23: Cytomegalovirus (HHV-5) Infections – Pipeline by Biotest AG, 2022
- Table 24: Cytomegalovirus (HHV-5) Infections – Pipeline by Chengdu Rongsheng Pharmaceutical Co Ltd, 2022
- Table 25: Cytomegalovirus (HHV-5) Infections – Pipeline by China Biologic Products Holdings Inc, 2022
- Table 26: Cytomegalovirus (HHV-5) Infections – Pipeline by China Immunotech Co Ltd, 2022
- Table 27: Cytomegalovirus (HHV-5) Infections – Pipeline by Citranvi Biosciences LLC, 2022
- Table 28: Cytomegalovirus (HHV-5) Infections – Pipeline by Cyrus Biotechnology Inc, 2022
- Table 29: Cytomegalovirus (HHV-5) Infections – Pipeline by Danuvius BioSciences, 2022
- Table 30: Cytomegalovirus (HHV-5) Infections – Pipeline by Evrys Bio, 2022
- Table 31: Cytomegalovirus (HHV-5) Infections – Pipeline by GSK plc, 2022
- Table 32: Cytomegalovirus (HHV-5) Infections – Pipeline by Helocyte Biosciences Inc, 2022
- Table 33: Cytomegalovirus (HHV-5) Infections – Pipeline by Hookipa Pharma Inc, 2022
- Table 34: Cytomegalovirus (HHV-5) Infections – Pipeline by Huinuo Biomedical Technology Co Ltd, 2022
- Table 35: Cytomegalovirus (HHV-5) Infections – Pipeline by iCELL Biotechnology Co Ltd, 2022
- Table 36: Cytomegalovirus (HHV-5) Infections – Pipeline by Immunetune BV, 2022
- Table 37: Cytomegalovirus (HHV-5) Infections – Pipeline by Karyopharm Therapeutics Inc, 2022
- Table 38: Cytomegalovirus (HHV-5) Infections – Pipeline by Lion TCR Pte Ltd, 2022
- Table 39: Cytomegalovirus (HHV-5) Infections – Pipeline by Memo Therapeutics AG, 2022
- Table 40: Cytomegalovirus (HHV-5) Infections – Pipeline by Merck & Co Inc, 2022
- Table 41: Cytomegalovirus (HHV-5) Infections – Pipeline by Microbiotix Inc, 2022
- Table 42: Cytomegalovirus (HHV-5) Infections – Pipeline by Moderna Inc, 2022
- Table 43: Cytomegalovirus (HHV-5) Infections – Pipeline by Nobelpharma Co Ltd, 2022
- Table 44: Cytomegalovirus (HHV-5) Infections – Pipeline by Okogen Inc, 2022
- Table 45: Cytomegalovirus (HHV-5) Infections – Pipeline by Phoenix Biotechnology Inc, 2022
- Table 46: Cytomegalovirus (HHV-5) Infections – Pipeline by Prosit Sole Biotechnology (Beijing) Co Ltd, 2022
- Table 47: Cytomegalovirus (HHV-5) Infections – Pipeline by Savoy Pharmaceuticals Inc, 2022
- Table 48: Cytomegalovirus (HHV-5) Infections – Pipeline by Shanxi Kangbao Biological Product Co Ltd, 2022
- Table 49: Cytomegalovirus (HHV-5) Infections – Pipeline by SL VaxiGen Inc, 2022
- Table 50: Cytomegalovirus (HHV-5) Infections – Pipeline by SpyBiotech Ltd, 2022
- Table 51: Cytomegalovirus (HHV-5) Infections – Pipeline by Stadius Biopharma LLC, 2022
- Table 52: Cytomegalovirus (HHV-5) Infections – Pipeline by Synklino ApS, 2022
- Table 53: Cytomegalovirus (HHV-5) Infections – Pipeline by Takeda Pharmaceutical Co Ltd, 2022
- Table 54: Cytomegalovirus (HHV-5) Infections – Pipeline by Trellis Bioscience Inc, 2022
- Table 55: Cytomegalovirus (HHV-5) Infections – Pipeline by VBI Vaccines Inc, 2022
- Table 56: Cytomegalovirus (HHV-5) Infections – Pipeline by Vichem Chemie Research Ltd, 2022
- Table 57: Cytomegalovirus (HHV-5) Infections – Pipeline by Viramatix Sdn Bhd, 2022
- Table 58: Cytomegalovirus (HHV-5) Infections – Pipeline by ViroKyne Therapeutics LLC, 2022
- Table 59: Cytomegalovirus (HHV-5) Infections – Pipeline by Zhuhai Trinomab Biotechnology Co Ltd, 2022
- Table 60: Cytomegalovirus (HHV-5) Infections – Dormant Projects, 2022
- Table 61: Cytomegalovirus (HHV-5) Infections – Dormant Projects, 2022 (Contd..1)
- Table 62: Cytomegalovirus (HHV-5) Infections – Dormant Projects, 2022 (Contd..2)
- Table 63: Cytomegalovirus (HHV-5) Infections – Dormant Projects, 2022 (Contd..3)
- Table 64: Cytomegalovirus (HHV-5) Infections – Dormant Projects, 2022 (Contd..4)
- Table 65: Cytomegalovirus (HHV-5) Infections – Dormant Projects, 2022 (Contd..5)
- Table 66: Cytomegalovirus (HHV-5) Infections – Discontinued Products, 2022
- List of Figures
- Figure 1: Number of Products under Development for Cytomegalovirus (HHV-5) Infections, 2022
- Figure 2: Number of Products under Development by Companies, 2022
- Figure 3: Number of Products under Development by Universities/Institutes, 2022
- Figure 4: Number of Products by Top 10 Targets, 2022
- Figure 5: Number of Products by Stage and Top 10 Targets, 2022
- Figure 6: Number of Products by Top 10 Mechanism of Actions, 2022
- Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Figure 8: Number of Products by Routes of Administration, 2022
- Figure 9: Number of Products by Stage and Routes of Administration, 2022
- Figure 10: Number of Products by Top 10 Molecule Types, 2022
- Figure 11: Number of Products by Stage and Top 10 Molecule Types, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.